Sol-Gel Technologies Ltd (SLGL)

$77.00 +2.17 (2.90%)
Market Cap 210.27M
Revenue (ttm) 19.39M
Net Income (ttm) -6.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.61%
Debt to Equity Ratio 0.00
Volume 18,554
Avg Vol 44,152
Day's Range N/A - N/A
Shares Out 2.81M
Stochastic %K 36%
Beta 1.26
Analysts Sell
Price Target $110.00

Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 931 3433
Address:
7 Golda Meir Street, Weizmann Science Park, Ness Ziona, Israel
weichsel1
weichsel1 Apr. 23 at 12:26 PM
$SLGL any news?
0 · Reply
DORIN95
DORIN95 Apr. 17 at 6:47 PM
$SLGL phase 3 soooonnnn
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 8 at 5:10 PM
$SLGL
0 · Reply
RafaelTheOne
RafaelTheOne Apr. 5 at 8:55 PM
$SLGL Still Unprofitable Despite Revenue Growth.
0 · Reply
weichsel1
weichsel1 Mar. 31 at 5:21 PM
$SLGL Talk about volatility..
0 · Reply
weichsel1
weichsel1 Mar. 30 at 7:44 PM
$SLGL any news Today?
0 · Reply
UltimateGuardians
UltimateGuardians Mar. 24 at 11:13 PM
$SLGL new filing
0 · Reply
Investerare_SAAB
Investerare_SAAB Mar. 24 at 8:43 PM
$SLGL $CVV $UGRO $VWAV $DXST PT1
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 5:26 PM
Midday Top Gainers PT2 $MKDW $NUCL $HUBCW $SLGL $HSPTU
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 3:22 PM
Top Gainers $PAVS $RBNE $FEED $SLGL $ANNA
0 · Reply
Latest News on SLGL
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

Mar 23, 2026, 9:38 PM EDT - 4 weeks ago

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

Mar 19, 2026, 8:53 AM EDT - 5 weeks ago

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 20, 2025, 7:30 AM EST - 5 months ago

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 15, 2025, 7:00 AM EDT - 9 months ago

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025, 7:15 AM EDT - 1 year ago

Sol-Gel Reports First Quarter 2025 Results

Sol-Gel Announces Reverse Share Split

May 1, 2025, 7:00 AM EDT - 1 year ago

Sol-Gel Announces Reverse Share Split

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Apr 17, 2025, 8:40 AM EDT - 1 year ago

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

Apr 7, 2025, 10:01 AM EDT - 1 year ago

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 15, 2024, 7:00 AM EST - 1 year ago

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 17, 2024, 11:27 AM EDT - 1 year ago

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 16, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel Technologies Announces Management Realignment

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Sol-Gel Technologies Announces Management Realignment

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 20, 2024, 7:00 AM EDT - 2 years ago

Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

May 16, 2024, 6:00 AM EDT - 2 years ago

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Nov 30, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Nov 28, 2023, 8:06 AM EST - 2 years ago

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Jun 6, 2023, 7:30 AM EDT - 3 years ago

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 20, 2023, 7:00 AM EDT - 3 years ago

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Mar 10, 2023, 7:00 AM EST - 3 years ago

Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

Sol-Gel Technologies Transcript: M&A Announcement

Jan 27, 2023, 8:30 AM EST - 3 years ago

Sol-Gel Technologies Transcript: M&A Announcement

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Jan 27, 2023, 7:29 AM EST - 3 years ago

Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Jan 27, 2023, 7:00 AM EST - 3 years ago

Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 4:00 AM EST - 3 years ago

Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Oct 3, 2022, 8:00 AM EDT - 3 years ago

Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 6:00 AM EDT - 4 years ago

Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 13, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Apr 25, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Apr 14, 2022, 8:30 AM EDT - 4 years ago

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Mar 30, 2022, 7:00 AM EDT - 4 years ago

Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Mar 25, 2022, 11:00 AM EDT - 4 years ago

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Dec 22, 2021, 4:05 PM EST - 4 years ago

Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Dec 21, 2021, 7:00 AM EST - 4 years ago

Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Nov 11, 2021, 7:00 AM EST - 4 years ago

Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Nov 9, 2021, 7:05 AM EST - 4 years ago

Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sep 22, 2021, 7:30 AM EDT - 4 years ago

Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Sep 9, 2021, 8:30 AM EDT - 5 years ago

Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Aug 4, 2021, 7:05 AM EDT - 5 years ago

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

Jul 27, 2021, 10:26 AM EDT - 5 years ago

Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Jul 27, 2021, 9:15 AM EDT - 5 years ago

Sol-Gel Technologies Announces FDA Approval of TWYNEO®

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Jul 20, 2021, 7:05 AM EDT - 5 years ago

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Sol-Gel Announces Pipeline Update and Future Development Plans

Jun 28, 2021, 5:10 AM EDT - 5 years ago

Sol-Gel Announces Pipeline Update and Future Development Plans

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Jun 28, 2021, 5:00 AM EDT - 5 years ago

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

Sol-Gel Technologies Transcript: Partnership

Jun 27, 2021, 8:00 PM EDT - 5 years ago

Sol-Gel Technologies Transcript: Partnership

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

May 13, 2021, 7:05 AM EDT - 5 years ago

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Apr 27, 2021, 12:03 PM EDT - 5 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX CYCN

weichsel1
weichsel1 Apr. 23 at 12:26 PM
$SLGL any news?
0 · Reply
DORIN95
DORIN95 Apr. 17 at 6:47 PM
$SLGL phase 3 soooonnnn
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 8 at 5:10 PM
$SLGL
0 · Reply
RafaelTheOne
RafaelTheOne Apr. 5 at 8:55 PM
$SLGL Still Unprofitable Despite Revenue Growth.
0 · Reply
weichsel1
weichsel1 Mar. 31 at 5:21 PM
$SLGL Talk about volatility..
0 · Reply
weichsel1
weichsel1 Mar. 30 at 7:44 PM
$SLGL any news Today?
0 · Reply
UltimateGuardians
UltimateGuardians Mar. 24 at 11:13 PM
$SLGL new filing
0 · Reply
Investerare_SAAB
Investerare_SAAB Mar. 24 at 8:43 PM
$SLGL $CVV $UGRO $VWAV $DXST PT1
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 5:26 PM
Midday Top Gainers PT2 $MKDW $NUCL $HUBCW $SLGL $HSPTU
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 3:22 PM
Top Gainers $PAVS $RBNE $FEED $SLGL $ANNA
0 · Reply
LewisDaKat
LewisDaKat Mar. 24 at 3:00 PM
$SLGL Sol-Gel Technologies Ltd. (NASDAQ: SLGL) Rises Sharply in 3/24 Early Trading Session https://marketwirenews.com/stock/slgl/news/sol-gel-technologies-ltd-nasdaq-slgl-rises-sharply-i-5471338706025919.html?utm_source=stocktwits
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 2:47 PM
Top Gainers PT2 $SLGL $CVV $UGRO $VWAV $DXST
0 · Reply
Ric_1M
Ric_1M Mar. 24 at 2:01 PM
$PAVS $RBNE $ANNA $SLGL $ELAB “The Chinese use two brush strokes to write the word 'crisis.' One brush stroke stands for danger; the other for opportunity. In a crisis, be aware of the danger--but recognize the opportunity.” John F. Kennedy
0 · Reply
topstockalerts
topstockalerts Mar. 24 at 1:54 PM
Top Gainers PT2 $ANNA $LICN $NTGR $SLGL $TAOP
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 24 at 12:49 PM
$SLGL (+8.8% pre) Sol-Gel Technologies prices $33.1 million share offering at $72 each https://ooc.bz/l/97025
0 · Reply
briefingcom
briefingcom Mar. 24 at 12:32 PM
$SLGL: Sol-Gel prices offering of 459,112 ordinary shares at $72.00 per share
0 · Reply
weichsel1
weichsel1 Mar. 24 at 12:23 PM
$SLGL 33 million dollar public offering that looks like a PIPE at 72 dollars https://finance.yahoo.com/markets/stocks/articles/sol-gel-technologies-ltd-announces-013800392.html
0 · Reply
ClassifiedTrades
ClassifiedTrades Mar. 24 at 10:55 AM
Premarket Watchlist — Mar 24, 2026 $PAVS +66.7% Float 0.1M $UGRO +26.3% Float 0.7M $AMIX +16.6% Float 10.5M $SLGL +11.8% Float 0.8M $EDBL +11.0% Float 0.5M Bot-generated premarket watchlist (educational). Not financial advice.
0 · Reply
weichsel1
weichsel1 Mar. 23 at 9:39 PM
$SLGL Range today is 62 to 75, and after market closes at 66, down 8, on "low" volume of 16k. Float is only 270,000 so 16k is still an impressive trading day..
0 · Reply
weichsel1
weichsel1 Mar. 16 at 3:01 PM
$SLGL bid ask is 72 / 89. Wow
0 · Reply
weichsel1
weichsel1 Mar. 9 at 7:37 PM
$SLGL 20 percent price swing inside a day.. 68 to 86. Nuts.
0 · Reply
TapeBenji
TapeBenji Mar. 8 at 7:56 AM
$EZRA Earnings call on March 10th. $SLGL Next Earnings Date: Wednesday, March 11, 2026 (Pre-market)Analyst Expectations: EPS of $0.39 and Revenue of $6.50 million.
0 · Reply